
AbbVie
A global biopharmaceutical company headquartered in the United States, focused on immunology, oncology, neuroscience, ophthalmology, and related therapeutic areas.
Last updated November 4, 2026
AI crawler reads
225requests
8AI- OpenAI136
- Meta33
- Perplexity22
- Amazon14
- Shape12
- +38
- Profile
- 175
- Controversies
- 17
- JSON · MD
- 0
- First read
- Oct 29, 2026
- Latest read
- Nov 17, 2026
From this site's server log
Overview
AbbVie is a global biopharmaceutical company headquartered in North Chicago, Illinois. It became an independent publicly traded company in 2013 after being separated from Abbott, taking with it Abbott’s established pharmaceutical research and commercial operations. AbbVie focuses on immunology, oncology, neuroscience, ophthalmology, gastroenterology, women’s health, and related therapeutic areas. Its portfolio has included Humira, Skyrizi, Rinvoq, Imbruvica, and other prescription medicines, as well as therapeutic and aesthetic products associated with the Allergan business. Humira was for many years a central product, while the company has sought to diversify its revenue base as biosimilar competition increased after the loss of key exclusivity protections. AbbVie has also expanded through research partnerships, licensing, and acquisitions, including the acquisition of Allergan. Its core business is the research, development, and commercialization of prescription medicines and related healthcare products; it is not a banking or general financial-services brand.
History
AbbVie was created as part of Abbott Laboratories’ separation of its research-based pharmaceutical operations. The company was formed in 2012 and began operating as an independent public company in January 2013. Its corporate name linked the Abbott heritage with “vie,” a word element associated with life. The new company inherited established medicines, research capabilities, employees, and commercial infrastructure, with Humira becoming its defining product. Humira’s success gave AbbVie a powerful position in immunology. The medicine was approved for a broad set of autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. At the same time, its importance made the company vulnerable to the eventual loss of exclusivity. AbbVie pursued patent and lifecycle-management strategies while developing replacement products and expanding into other therapeutic areas. During its first years, AbbVie supplemented internal research with external alliances and acquisitions. In 2014 it acquired ImmuVen and entered collaborations with Infinity Pharmaceuticals and Calico. The company abandoned its proposed acquisition of Shire in 2014 after changes to United States tax rules undermined the transaction’s intended structure; AbbVie paid a reported $1.6 billion termination fee. In 2015 it acquired Pharmacyclics, obtaining Imbruvica and increasing its presence in hematologic oncology. In 2016 it acquired Stemcentrx and expanded collaborations in cystic fibrosis, inflammatory bowel disease, oncology, synthetic biology, and targeted immunotherapy. The largest transformation came through the Allergan transaction. Announced in 2019 and completed in 2020, the approximately $63 billion acquisition added Botox and Allergan’s aesthetics business, as well as products and development assets in neuroscience, eye care, gastroenterology, and other fields. Regulatory review required divestitures including brazikumab and the pancreatic enzyme products Zenpep and Viokace. The acquisition diversified AbbVie beyond immunology and created a much broader commercial platform. The COVID-19 pandemic produced a short-lived investigation of Kaletra, the lopinavir/ritonavir combination used for HIV. AbbVie worked with health authorities to evaluate whether the medicine could have value against COVID-19, but an early randomized study did not demonstrate usefulness in severe disease. In the same period, Israel announced it could override patent protections for access to the medicine; AbbVie subsequently stated that it would not enforce its Kaletra patents. After 2020, AbbVie continued to build positions in immunology, oncology, and neuroscience. Allergan Aesthetics acquired Soliton in 2021, while AbbVie acquired TeneoOne and its multiple-myeloma program. In 2022 it bought Syndesi Therapeutics and DJS Antibodies, adding neuroscience and antibody research capabilities. Humira biosimilar competition began to intensify in 2023, increasing the importance of Skyrizi and Rinvoq as successor growth products. In 2024 AbbVie completed acquisitions of ImmunoGen, Landos Biopharma, and Cerevel Therapeutics. ImmunoGen brought Elahere, an antibody-drug conjugate for ovarian cancer. Landos added NX-13, an investigational gastrointestinal immunology asset. Cerevel expanded the neuroscience pipeline with programs aimed at disorders including schizophrenia, Parkinson’s disease, and other neurological conditions. AbbVie also acquired Aliada Therapeutics in 2024 to add another neuroscience platform. The company’s growth strategy combines commercial execution with business development. AbbVie promotes prescription products through healthcare professionals, patient-support programs, digital channels, television, and disease-awareness initiatives. Its public-facing communications increasingly focus on patient experiences and the effect of chronic disease on everyday life. The “I Am” corporate campaign, for example, portrayed people with psoriasis, Parkinson’s disease, blood cancer, and other conditions through identities broader than their diagnoses, while also featuring scientists involved in developing medicines. AbbVie has also faced sustained criticism. Allegations have concerned patent thickets and other methods that may delay biosimilar competition, drug-pricing practices, marketing arrangements, tax planning, and opioid promotion by an Allergan subsidiary. The company settled some disputes financially while denying wrongdoing in certain cases. A United Kingdom court dismissed AbbVie’s 2018 procurement challenge against NHS England concerning hepatitis C treatments. These issues have made AbbVie a recurring subject in debates about pharmaceutical competition, affordability, and intellectual-property policy. In June 2024, Robert A. Michael became chief executive officer and Richard Gonzalez became executive chairman. AbbVie continues to focus on replacing Humira-related revenue with growth in immunology, aesthetics, oncology, and neuroscience, while using acquisitions and licensing agreements to replenish its research pipeline. AbbVie was separated from Abbott in 2013 and began operating as an independent publicly traded biopharmaceutical company. At its formation, the company inherited a portfolio of established medicines and research assets, including Humira, which became a major commercial foundation in immunology. Over time, AbbVie expanded its activities across immunology, oncology, neuroscience, ophthalmology, gastroenterology, and related fields through internal research, collaborations, licensing, and acquisitions. As biosimilar competition increased following the weakening of key exclusivity protections for Humira, the company placed greater emphasis on newer immunology medicines such as Skyrizi and Rinvoq and continued to broaden its therapeutic portfolio. The acquisition of Allergan also expanded AbbVie’s presence in aesthetics, neuroscience, and ophthalmology. Its development has generally combined cash generation from established products with investment in research, new product launches, and portfolio-building transactions. Specific financial figures, transaction values, and market-level sales data are omitted here because no verifiable source URLs were provided.
- 2024
ImmunoGen acquisition closes
[2]AbbVie completed its acquisition of ImmunoGen and added Elahere to its oncology portfolio.
- 2024
Leadership transition
[7]Robert Michael became CEO and Richard Gonzalez became executive chairman.
- 2023
Humira biosimilar competition begins
[1]Biosimilar versions of Humira began entering the United States market, intensifying pressure on AbbVie’s former leading product.
- 2020
Allergan transaction closes
[1]The Allergan acquisition closed, adding Botox, aesthetics, neuroscience, and other businesses. AbbVie completed the acquisition of Allergan, incorporating its aesthetics, ophthalmology, and neuroscience products and operations into the company's portfolio.
- 2019
Announced acquisition of Allergan
AbbVie announced the acquisition of Allergan to expand its business in aesthetics, neuroscience, ophthalmology, and other specialty therapeutic areas.
- 2016
Stemcentrx acquisition
[1]AbbVie announced an acquisition of Stemcentrx valued at up to $9.8 billion, expanding its oncology pipeline.
- 2015
Pharmacyclics acquisition
[1]AbbVie acquired Pharmacyclics, bringing Imbruvica into its oncology portfolio.
- 2013
Public-company launch
[1]AbbVie began trading independently in January 2013. AbbVie was spun off from Abbott, taking over part of its pharmaceutical R&D and commercialization business, and became an independent publicly traded company.
- 2012
AbbVie is formed
[1]AbbVie was established as the planned spin-off of Abbott Laboratories’ research-based pharmaceutical business.
Products and positioning
A diversified research-driven biopharmaceutical company with particular strength in immunology, specialty medicines, aesthetics, oncology, and neuroscience. AbbVie positions itself around innovative therapies for serious and chronic diseases, supported by global commercialization and acquisitions that replenish its pipeline. A global research-based biopharmaceutical company focused on immunology, oncology, neuroscience, ophthalmology, gastroenterology, and aesthetics.
Immunology biologic
Humira
Humira is the brand name for adalimumab, a tumor-necrosis-factor inhibitor administered by injection. It has been used across a wide range of autoimmune and inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, Crohn’s disease, and ulcerative colitis. Humira was AbbVie’s foundational commercial product, but its importance also exposed the company to substantial revenue pressure when biosimilar competition began. An adalimumab-based biologic used for a range of inflammatory and autoimmune diseases. It was one of AbbVie’s defining products during the company’s early development and established a major commercial foundation in immunology.
Immunology biologic
Skyrizi
Skyrizi is risankizumab, an interleukin-23 inhibitor used for several immune-mediated diseases. Its indications include plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. AbbVie has developed Skyrizi as one of its principal post-Humira growth products, supported by clinical expansion and substantial patient and professional communications. An immunology medicine targeting a specific inflammatory pathway and used in selected chronic inflammatory diseases. It is one of AbbVie’s key newer immunology products developed to strengthen the portfolio beyond Humira.
Immunology small molecule drug
Rinvoq
Rinvoq is upadacitinib, an oral Janus kinase inhibitor used in inflammatory and autoimmune conditions, including certain forms of arthritis, atopic dermatitis, Crohn’s disease, and ulcerative colitis. Its oral format and expanding indications make it a central component of AbbVie’s immunology strategy and a major successor to Humira. An oral immunomodulatory medicine used in selected inflammatory and autoimmune conditions. It represents AbbVie’s effort to build an oral immunology franchise alongside its biologic therapies.
Medical aesthetics and therapeutic medicine
Botox
Botox is a botulinum toxin product used for both aesthetic procedures and therapeutic indications. AbbVie obtained the brand through the Allergan acquisition. The business operates across cosmetic treatment and medical applications, including certain neurological and muscular conditions, and is one of AbbVie’s most recognizable consumer-facing offerings. A botulinum toxin brand used in selected therapeutic indications and aesthetic procedures. It became an important part of AbbVie’s aesthetics and specialty-care portfolio through the integration of Allergan.
Oncology medicine
Imbruvica
Imbruvica is ibrutinib, a targeted oncology medicine used in several blood cancers and related hematological malignancies. AbbVie obtained rights and commercial participation through its 2015 acquisition of Pharmacyclics. The product helped establish AbbVie as a significant oncology company, although it has faced competition and pricing scrutiny. A targeted oncology medicine used in certain hematologic malignancies. It helped AbbVie expand beyond immunology into oncology, with specific indications and availability subject to local regulatory approvals.
Oncology medicine
Venclexta
Venclexta is venetoclax, a medicine used in the treatment of certain leukemias and lymphomas. It is part of AbbVie’s blood-cancer portfolio and was developed through collaboration with Genentech and Roche. Its mechanism and clinical use place it within the company’s targeted-therapy strategy in hematologic oncology.
Neuroscience medicine
Vraylar
Vraylar is cariprazine, a medicine used for schizophrenia and bipolar disorder. The product is part of AbbVie’s neuroscience portfolio and illustrates the company’s effort to build commercial depth beyond immunology and oncology. A prescription medicine used in selected psychiatric and mood-disorder indications. It is one of the representative brands in AbbVie’s neuroscience portfolio, with availability and indications subject to local approvals.
Antiviral medicine
Mavyret
Mavyret is glecaprevir/pibrentasvir, a fixed-dose antiviral combination used to treat hepatitis C virus infection. It represents AbbVie’s contribution to direct-acting antiviral therapy and its broader focus on medicines addressing significant infectious diseases.
Bispecific oncology antibody
Epkinly
Epkinly is epcoritamab, a bispecific antibody developed with Genmab for certain B-cell blood cancers. It is designed to engage immune cells against malignant B cells and adds a newer immuno-oncology modality to AbbVie’s hematology portfolio.
Antibody-drug conjugate · 2022
Elahere
Elahere is an antibody-drug conjugate obtained through AbbVie’s acquisition of ImmunoGen. It is used in certain ovarian cancers and gives AbbVie a commercial foothold in a specialized oncology technology area. The acquisition was intended to accelerate AbbVie’s development and commercialization of the product.
Controversies
2024
Trade-secret lawsuit against BeiGene
AbbVie sued BeiGene, alleging that a former AbbVie scientist took confidential information that was used in developing a competing blood-cancer treatment. The allegations were disputed and remained litigation claims rather than established findings.
2023
AbbVie files patent lawsuit against BeiGene over Brukinsa
AbbVie’s Pharmacyclics unit filed a lawsuit against BeiGene in federal court in Delaware, alleging that BeiGene’s Brukinsa infringes a patent on AbbVie’s Imbruvica. AbbVie sought a declaratory judgment of infringement and damages; BeiGene said it would vigorously defend against the allegations.
2022
Opioid-marketing settlement involving Allergan
AbbVie agreed to pay up to $2.37 billion to resolve U.S. litigation involving alleged opioid marketing by its Allergan unit. AbbVie denied wrongdoing.
2021
Senate investigation into tax practices
The United States Senate Finance Committee examined whether AbbVie used provisions of the 2017 tax law and offshore intellectual-property structures to reduce its U.S. tax liability.
2021
BTL and AbbVie settle patent dispute
BTL announced that it had resolved its patent infringement claims against AbbVie related to BTL's muscle stimulation technology. Under the settlement, AbbVie will pay BTL an undisclosed amount, and pending litigation between the parties will be dismissed.
2021
AbbVie files second suit against Alvotech
AbbVie brought a second action against Alvotech hf. in the Northern District of Illinois, alleging patent infringement in connection with Alvotech’s proposed HUMIRA biosimilar.
2021
Alvotech files suit against AbbVie over Humira patents
Alvotech USA and Alvotech hf filed a declaratory-judgment complaint against AbbVie in the Eastern District of Virginia, alleging that patents in AbbVie’s Humira portfolio were invalid or unenforceable and seeking declaratory judgments of non-infringement and invalidity.
2020
Humira nurse-ambassador allegations
AbbVie agreed to pay $24 million to resolve allegations concerning kickbacks connected with promotion of Humira through nurse-ambassador programs.
2020
AbbVie settles California allegations over HUMIRA marketing
AbbVie reached a settlement with California over allegations that it violated the state’s Insurance Frauds Prevention Act. The agreement requires changes to its HUMIRA marketing practices and a $24 million payment; AbbVie continued to deny wrongdoing.
2018
TriCor marketing settlement
AbbVie agreed to pay $25 million to resolve allegations that unlawful kickback arrangements were used to promote TriCor. The resolution did not establish a criminal conviction by itself, and the company’s legal position should be distinguished from the allegations.
Brand decisions
2026
AbbVie completes acquisition of Apogee TherapeuticsM&ABackground
AbbVie completed its acquisition of Apogee Therapeutics, as reported in the release dated Oct. 30.
2024
AbbVie completes acquisition of ImmunoGenM&ABackground
AbbVie announced that it had completed its previously announced acquisition of ImmunoGen.
2023
AbbVie announces acquisition of Cerevel TherapeuticsM&ABackground
AbbVie announced it will acquire Cerevel Therapeutics for $45 per share in cash, valuing the drugmaker at about $8.7 billion. The transaction is subject to regulatory approvals, Cerevel shareholder approval and other customary closing conditions.
2023
AbbVie announces acquisition of MitokininM&ABackground
AbbVie announced its acquisition of discovery-stage biotechnology company Mitokinin in a deal worth over $650 million. The agreement gives AbbVie access to Mitokinin’s lead PINK1 activator compound; Mitokinin’s shareholders are eligible for additional payments tied to development and commercial milestones, as well as royalties.
2023
AbbVie completes acquisition of MitokininM&ABackground
AbbVie exercised its exclusive right and completed its acquisition of biotechnology company Mitokinin. Under the agreement, AbbVie will pay Mitokinin shareholders $110 million at closing, with potential additional milestone payments and royalties.
2022
AbbVie acquires Syndesi TherapeuticsM&ABackground
Novo Holdings announced that its portfolio company Syndesi Therapeutics had been acquired by AbbVie in a deal valued at up to US$1 billion, including US$130 million upfront.
2022
AbbVie announces acquisition of Syndesi TherapeuticsM&ABackground
AbbVie announced its acquisition of Syndesi Therapeutics under a $1 billion agreement, including a $130 million upfront payment and milestone payments of up to $870 million.
2021
AbbVie to acquire TeneoOneM&ABackground
AbbVie exercised its option to acquire TeneoOne, the Teneobio affiliate developing the cancer drug TNB-383B, for an undisclosed sum.
2020
AbbVie completes acquisition of AllerganM&ABackground
AbbVie announced that it had completed its acquisition of Allergan; the transaction had received the required government regulatory approvals and approval from the High Court of Ireland.
Recent events
Nxera and AbbVie enter global licensing agreement for NXE0033744[22]
Reported
Nxera Pharma entered into an exclusive global licensing agreement with AbbVie for NXE0033744, an investigational oral EP4 receptor agonist being developed for inflammatory bowel disease. AbbVie will receive exclusive worldwide rights to develop and commercialise the candidate for IBD; the transaction remains subject to customary antitrust clearances.
AbbVie completes acquisition of Apogee Therapeutics[8]
Reported
AbbVie completed its acquisition of Apogee Therapeutics, as reported in the release dated Oct. 30.
- Unconfirmed
US FDA approves AbbVie's drug for Parkinson's disease[23]
Reported
The US Food and Drug Administration approved AbbVie's drug for Parkinson's disease, as reported by Reuters.
AbbVie reports third-quarter 2026 results[24]
AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% year over year, and adjusted EPS of $3.82.
AbbVie raises full-year adjusted EPS guidance[24]
AbbVie raised its full-year adjusted EPS guidance from $13.76–$13.96 to $13.95–$13.99.
AbbVie completes acquisition of ImmunoGen[9]
Reported
AbbVie announced that it had completed its previously announced acquisition of ImmunoGen.
AbbVie cuts first-quarter earnings outlook[9]
Reported
AbbVie revised down its first-quarter adjusted income-per-share outlook to $2.26–$2.30 from its previous $2.30–$2.34 range. It reaffirmed its annual adjusted income-per-share outlook of $11.05–$11.25.
DISCO Pharmaceuticals raises €20 million in seed financing[25]
Reported
DISCO Pharmaceuticals raised €20 million in seed financing, backed by an investor syndicate that included Sofinnova Partners, Panakes Partners, M Ventures and AbbVie Ventures.
AbbVie announces acquisition of Cerevel Therapeutics[10]
Reported
AbbVie announced it will acquire Cerevel Therapeutics for $45 per share in cash, valuing the drugmaker at about $8.7 billion. The transaction is subject to regulatory approvals, Cerevel shareholder approval and other customary closing conditions.
AbbVie announces acquisition of Mitokinin[11]
Reported
AbbVie announced its acquisition of discovery-stage biotechnology company Mitokinin in a deal worth over $650 million. The agreement gives AbbVie access to Mitokinin’s lead PINK1 activator compound; Mitokinin’s shareholders are eligible for additional payments tied to development and commercial milestones, as well as royalties.
Sources75 sources
- 1AbbVieen.wikipedia.org
- 2AbbVie Completes Acquisition of ImmunoGennews.abbvie.com
- 3AbbVie Completes Acquisition of Landos Biopharmanews.abbvie.com
- 4Explore the Human Side of AbbVie’s I Am Campaignmmm-online.com
- 5AbbVie Continues with Extreme Sporting Rinvoq TV Ad Themefiercepharma.com
- 6AbbVie Corporate Campaign Celebrates Patients and Scientistsfiercepharma.com
- 7Leadership transitionnews.abbvie.com
- 8AbbVie completes acquisition of Apogee Therapeuticsthemarketsdaily.com
- 9AbbVie completes acquisition of ImmunoGenrttnews.com
- 10AbbVie announces acquisition of Cerevel Therapeuticseconotimes.com
- 11AbbVie announces acquisition of Mitokininpmlive.com
- 12AbbVie completes acquisition of Mitokininrttnews.com
- 13AbbVie acquires Syndesi Therapeuticsprnewswire.com
- 14AbbVie announces acquisition of Syndesi Therapeuticspmlive.com
- 15AbbVie to acquire TeneoOnemedcitynews.com
- 16AbbVie completes acquisition of Allerganhealth.people.com.cn
- 17AbbVie files patent lawsuit against BeiGene over Brukinsapmlive.com
- 18BTL and AbbVie settle patent disputeprnewswire.com
- 19AbbVie files second suit against Alvotechjdsupra.com
- 20Alvotech files suit against AbbVie over Humira patentsjdsupra.com
- 21AbbVie settles California allegations over HUMIRA marketingjurist.org
- 22Nxera与艾伯维就NXE0033744达成全球许可协议pharmatimes.com
- 23美国FDA批准艾伯维帕金森病药物news.google.com
- 24艾伯维公布2026年第三季度业绩eeo.com.cn
- 25DISCO Pharmaceuticals获得2,000万欧元种子融资biospace.com
- 26FDA批准EPKINLY用于成人弥漫性大B细胞淋巴瘤itbusinessnet.com
- 27FDA批准Linzess用于治疗儿童功能性便秘healio.com
- 28FDA加速批准Epkinlyhealio.com
- 29AbbVie终止与BioArctic的合作prnewswire.com
- 30FDA 批准 Skyrizi 用于成人活动性银屑病关节炎healio.com
- 31FDA批准RINVOQ用于治疗银屑病关节炎finanznachrichten.de
- 32FDA批准艾伯维Qulipta用于预防偏头痛finanznachrichten.de
- 33FDA批准Botox扩大成人上肢痉挛适应症标签healio.com
- 34FDA批准Dalvance用于儿童感染治疗healio.com
- 35AbbVie与Caraway合作开发帕金森病疗法biospace.com
- 36Capsida Biotherapeutics获得1.4亿美元资金jdsupra.com
- 37Capsida与AbbVie宣布基因疗法合作prnewswire.com
- 38Pharmaron宣布收购ABL生产基地的协议finanznachrichten.de
- 39FDA批准Humira用于儿童溃疡性结肠炎finanznachrichten.de
- 40天境生物与艾伯维宣布全球战略合作tech.sina.com.cn
- 41艾伯维与天境生物就lemzoparlimab达成全球授权协议finance.sina.com.cn
- 42安进、艾伯维和武田启动新冠治疗联合试验pacbiztimes.com
- 43AbbVie 与 Genmab 癌症疗法合作financialpost.com
- 44艾伯维与Genmab签署广泛合作协议finanznachrichten.de
- 45AbbVie 合作开发 COVID-19 抗体hospimedica.com
- 46FDA批准AbbVie治疗肌瘤相关月经量过多的药物timesnownews.com
- 47Synlogic与AbbVie终止IBD合作prnewswire.com
- 48托马斯·C·弗雷曼当选艾伯维董事pharmatimes.com
- 49Nitrome完成3,800万美元A轮融资finanznachrichten.de
- 50Alkem Laboratories同意收购AbbVie的Dronabinol相关资产equitybulls.com
- 51药企同意下调部分药品在华售价zaobao.com.sg
- 52艾伯维调整2019年业绩指引prnewswire.com
- 53AbbVie与囊性纤维化基金会宣布许可合作prnewswire.com
- 54天境生物今日宣布与艾伯维签署战略合作与高瓴资本领投的私募配售_金融资讯_行业_中金在线hy.stock.cnfol.com
- 55天境生物与艾伯维宣布建立肿瘤免疫创新药的全球战略合作_金融资讯_行业_中金在线hy.stock.cnfol.com
- 56总营收或突破500亿!艾伯维(ABBV.US)完成对艾尔建(AGN.US)的收购,巨头即将诞生?finance.sina.com.cn
- 57AbbVie Completes Transformative Acquisition of Allerganprnewswire.com
- 58AbbVie Inc. Completes Acquisition of Allergan plcprnewswire.com
- 59AbbVie Raises 2023 Adj. EPS Guidance; Announces 2024 Dividend Increasefinanznachrichten.de
- 60AbbVie Reports First-Quarter 2020 Financial Resultsprnewswire.com
- 61AbbVie Reports Third-Quarter 2021 Financial Resultsprnewswire.com
- 62Alkem Labs acquires anti-nausea drug Marinol from AbbVie for $10 million- Moneycontrol.commoneycontrol.com
- 63BRIEF—AbbVie finally completes acquisition of Allerganthepharmaletter.com
- 64Capsida unveils $140M, AbbVie alliance & tech that takes gene therapy to the brain - MedCity Newsmedcitynews.com
- 65DISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financingprnewswire.com
- 66FDA Approves AbbVie's Qulipta For Preventive Treatment Of Migraine In Adultsrttnews.com
- 67FDA Approves AbbVie's Rinvoq As Once-Daily Pill For Crohn's Disease In Adultsfinanznachrichten.de
- 68FDA Approves AbbVie's Rinvoq For Treatment Of Active Non-radiographic Axial Spondyloarthritisfinanznachrichten.de
- 69FDA Approves AbbVie's Rinvoq To Treatment Active Ankylosing Spondylitisfinanznachrichten.de
- 70FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoqfinance.yahoo.com
- 71FDA Approves QULIPTA , the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraineinvestingnews.com
- 72FDA approves Rinvoq as first oral therapy for moderate to severe Crohnâs diseasehealio.com
- 73FDA approves Rinvoq as first pill to treat moderate-to-severe Crohn's diseasewxyz.com
- 74FDA approves Rinvoq for atopic dermatitishealio.com
- 75FDA Approves Upadacitinib (Rinvoq) for Crohn's Diseasemedscape.com
Cite this profile: Cite the canonical profile. /brandpedia/abbvie · Editorial policy · How profiles are compiled